JF
GLMD icon

Jump Financial’s Galmed Pharmaceuticals GLMD Stock Holding History

Jump Financial’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-93
Closed -$51K – 1235
2021
Q2 		$51K Buy
93
+5
+6% +$2.72K ﹤0.01% 1028
2021
Q1 		$55K Buy
+88
New +$60.9K 0.01% 873

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jump Financial's GLMD Position: Q3 2021 in Review

Jump Financial sold out of Galmed Pharmaceuticals (GLMD) in Q3 2021, closing a stake of 93 shares — an estimated $51K sold.

Jump Financial first reported a position in GLMD in Q1 2021 and held it in 2 quarters. The position peaked at $55K in Q1 2021. 26 funds tracked by Wall St. Rank hold GLMD as of Q3 2021.

  • Jump Financial reported no remaining Galmed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jump Financial sold 93 Galmed Pharmaceuticals shares in Q3 2021, an estimated $51K.
  • Jump Financial first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Jump Financial's Galmed Pharmaceuticals position peaked at $55K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2021.

Based on Jump Financial's 13F filing for Q3 2021, filed 12 Nov 2021.